Sage Therapeutics Inc (NASDAQ: SAGE) kicked off on Friday, down -5.03% from the previous trading day, before settling in for the closing price of $5.67. Over the past 52 weeks, SAGE has traded in a range of $4.62-$28.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 3395.58% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 28.04%. With a float of $53.88 million, this company’s outstanding shares have now reached $61.17 million.
In an organization with 487 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 91.75%, operating margin of -349.3%, and the pretax margin is -317.29%.
Sage Therapeutics Inc (SAGE) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sage Therapeutics Inc is 11.92%, while institutional ownership is 85.29%. The most recent insider transaction that took place on Dec 10 ’24, was worth 41,441.
Sage Therapeutics Inc (SAGE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 28.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.80% during the next five years compared to -2.28% drop over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Take a look at Sage Therapeutics Inc’s (SAGE) current performance indicators. Last quarter, stock had a quick ratio of 10.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.58, a number that is poised to hit -1.53 in the next quarter and is forecasted to reach -3.81 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Let’s dig in a bit further. During the last 5-days, its volume was 1.17 million. That was better than the volume of 0.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 62.43%. Additionally, its Average True Range was 0.39.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 11.22%, which indicates a significant decrease from 40.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.68% in the past 14 days, which was lower than the 73.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.22, while its 200-day Moving Average is $10.65. However, in the short run, Sage Therapeutics Inc’s stock first resistance to watch stands at $5.73. Second resistance stands at $6.07. The third major resistance level sits at $6.42. If the price goes on to break the first support level at $5.04, it is likely to go to the next support level at $4.69. The third support level lies at $4.35 if the price breaches the second support level.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
The company with the Market Capitalisation of 312.86 million has total of 61,173K Shares Outstanding. Its annual sales at the moment are 86,460 K in contrast with the sum of -541,490 K annual income. Company’s last quarter sales were recorded 11,870 K and last quarter income was -93,550 K.
